The healthcare sector experienced a sharp rally today, with the CRO concept surging 5.65% on Tonghuashun. Seven companies, including Wuxi Apptec and Asymchem, hit their daily price limits, while Pharmaron advanced by 10.67%. The innovative drug sector also benefited, rising by 2%. After a prolonged period of stagnation, what triggered this sudden collective surge in healthcare stocks? The answer lies in the strong performance of the industry leader, Wuxi Apptec.

Upon releasing its half-year report, the company surpassed expectations across all key metrics, including revenue, net profit, gross margin, and performance guidance. Revenue for the first half reached 28.9 billion yuan, representing a nearly 39% year-on-year increase. Net profit exceeded 11 billion yuan for the first time, a growth of over 29% compared to the previous year. The second quarter was particularly impressive: single-quarter revenue hit 16.46 billion yuan, a sequential increase of 32.3%, indicating a clear acceleration. Non-GAAP net profit nearly doubled year-on-year, and the gross margin reached 56.56%, setting a new record. Initially, the company had projected a growth rate of 18% to 22% for the year, but the strong half-year performance prompted an upward revision to a 35% to 39% range.

Examining the business segments, the small molecule development and production business surged by 72%, nearly double the overall growth rate. The peptide business capitalized on the GLP-1 weight-loss drug trend, posting a growth rate of 44.3%. Some may question how the company has fared amid repeated U.S. proposals and investigations targeting Wuxi Apptec. The reality is that the company has leveraged its engineering talent advantage to maintain efficient delivery, retaining a robust order book. Outstanding orders reached 66.4 billion yuan, a year-on-year increase of over 25%. In this industry, the process of re-registration, validation, and approval can take a year or more. Given that new drug development is a race against time, overseas pharmaceutical companies are well aware of the cost-benefit calculus.

The "water sellers" for innovative drugs are leading the recovery. Prices for experimental monkeys have soared to 200,000 yuan each amid supply shortages. The CRO leader Wuxi Apptec has reported exceptional financial results and raised its capital expenditure ceiling to 8.5 billion yuan for expansion. However, analysts caution that a high base for GLP-1 drugs and geopolitical risks remain significant challenges. This raises the question: is the innovative drug sector experiencing a genuine turnaround, or is this merely a temporary resurgence?